Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 7/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 7/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.35 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13519808 | 0.89 | ADORA2A (0.41) | ADORA2ACSNK2A2CSNK2A1TNK2ACVRL1 | |
| SCHEMBL647116 | 0.89 | ADORA2A (0.41) | ADORA2ACSNK2A2CSNK2A1TNK2ACVRL1 | |
| SCHEMBL645943 | 0.89 | ADORA2A (0.41) | ADORA2ACSNK2A2CSNK2A1PIK3CDTNK2 | |
| SCHEMBL646007 | 0.85 | ADORA2A (0.41) | ADORA2ATNK2ACVRL1 | |
| SCHEMBL13531971 | 0.85 | ADORA2A (0.41) | ADORA2ATNK2ACVRL1 | |
| SCHEMBL13519782 | 0.84 | ADORA2A (0.44) | ADORA2APIK3CDTNK2ACVRL1 | |
| SCHEMBL13531953 | 0.83 | ADORA2A (0.43) | ADORA2APIK3CDTNK2ACVRL1 | |
| SCHEMBL13531963 | 0.82 | ADORA2A (0.43) | ADORA2AACVRL1 | |
| SCHEMBL646044 | 0.82 | ADORA2A (0.43) | ADORA2APIK3CDACVRL1 | |
| SCHEMBL7598953 | 0.82 | ADORA2A (0.43) | ADORA2APIK3CDTNK2ACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440813-B2 | Antiviral nucleoside analogs | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440813-B2 | Antiviral nucleoside analogs | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2535345-A1 | Anticancer nucleoside analogs | BioCryst Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| EP-2114980-B1 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARM INC (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-01-21 | — | — | US | disclosed |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-01-21 | — | — | US | disclosed |
| WO-2008089105-A2 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | TYMP, SAMHD1, TYMS | ADORA2A 795/4885CSNK2A2 3359/4885CSNK2A1 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.